A Study to Investigate the Exposure of Budesonide, Glycopyrronium, and Formoterol (BGF) Delivered by Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) Compared to a Hydrofluoroalkane (HFA) Propellant MDI in Healthy Adults

• Status: COMPLETED
• Trial end date: 2025-06-01

Summary

This study aims to assess the bioequivalence of the total systemic exposure and safety of budesonide, glycopyrronium, and formoterol (160/14.4/4.8 g/actuation) when administered as BGF MDI HFO compared with BGF MDI HFA in healthy participants.

• Phase: PHASE1

Details

• Lead Sponsor: AstraZeneca
• Collaborator: Parexel
• Treatments: Budesonide